Poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors as maintenance therapy in women with newly diagnosed ovarian cancer: a systematic review and meta-analysis.
Hongyan ChengJunjun YangHuixin LiuYang XiangPublished in: Archives of gynecology and obstetrics (2021)
PARP inhibitor maintenance therapy significantly prolongs the PFS of patients with newly diagnosed ovarian cancer, especially in HRD positive patients. The diagnostic test used to determine HRD status plays an important role in guiding PARP inhibitor maintenance therapy. Compared with placebo, the effect of PARP inhibitors on ovarian cancer was probably not affected by the International Federation of Gynecology and Obstetrics stage status, response to first-line chemotherapy, and residual macroscopic disease after debulking surgery.
Keyphrases
- newly diagnosed
- dna damage
- dna repair
- end stage renal disease
- chronic kidney disease
- minimally invasive
- ejection fraction
- clinical trial
- oxidative stress
- neoadjuvant chemotherapy
- coronary artery disease
- prognostic factors
- lymph node
- peritoneal dialysis
- percutaneous coronary intervention
- rectal cancer
- structural basis